Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization.

Anand S, Thomas S, Hyslop T, Adcock J, Corbet K, Gasparetto C, Lopez R, Long GD, Morris AK, Rizzieri DA, Sullivan KM, Sung AD, Sarantopoulos S, Chao NJ, Horwitz ME.

Biol Blood Marrow Transplant. 2017 Apr 6. pii: S1083-8791(17)30389-0. doi: 10.1016/j.bbmt.2017.04.001. [Epub ahead of print]

PMID:
28392378
2.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.

Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulos S, Kang Y, Long GD, Horwitz ME, Lopez RD, Sullivan KM, Rizzieri DA, Chao NJ, Gasparetto C.

Biol Blood Marrow Transplant. 2017 Feb;23(2):262-268. doi: 10.1016/j.bbmt.2016.11.010. Epub 2016 Nov 14.

PMID:
27856369
3.

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.

Horwitz ME, Chao NJ, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, McDonald C, Waters-Pick B, Stiff P, Wease S, Peled A, Snyder D, Cohen EG, Shoham H, Landau E, Friend E, Peleg I, Aschengrau D, Yackoubov D, Kurtzberg J, Peled T.

J Clin Invest. 2014 Jul;124(7):3121-8. doi: 10.1172/JCI74556. Epub 2014 Jun 9.

4.

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA.

Biol Blood Marrow Transplant. 2014 Feb;20(2):257-63. doi: 10.1016/j.bbmt.2013.11.010. Epub 2013 Nov 20.

5.

A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.

Held LA, Rizzieri D, Long GD, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Horwitz ME, Chao NJ, Gasparetto C.

Cancer Invest. 2013 Mar;31(3):172-6. doi: 10.3109/07357907.2012.756109. Epub 2013 Feb 13.

PMID:
23406188
6.

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.

Kanda J, Kaynar L, Kanda Y, Prasad VK, Parikh SH, Lan L, Shen T, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, Winkel S, McPherson J, Kurtzberg J, Chao NJ, Horwitz ME.

Bone Marrow Transplant. 2013 Jul;48(7):926-31. doi: 10.1038/bmt.2012.279. Epub 2013 Jan 21.

7.

Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.

Spasojevic I, da Costa LR, Horwitz ME, Long GD, Sullivan KM, Chute JP, Gasparetto C, Morris A, Chao NJ, Rizzieri DA.

Cancer Invest. 2012 Nov;30(9):679-82. doi: 10.3109/07357907.2012.726386. Epub 2012 Sep 28. No abstract available.

8.

Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation.

Kanda J, Chiou LW, Szabolcs P, Sempowski GD, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, McPherson J, Hale J, Livingston JA, Broadwater G, Niedzwiecki D, Chao NJ, Horwitz ME.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1664-1676.e1. doi: 10.1016/j.bbmt.2012.06.005. Epub 2012 Jun 12.

9.

Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.

Jagasia MH, Abonour R, Long GD, Bolwell BJ, Laport GG, Shore TB, Durrant S, Szer J, Chen MG, Lizambri R, Waller EK.

Bone Marrow Transplant. 2012 Oct;47(10):1350-5. doi: 10.1038/bmt.2011.261. Epub 2012 Feb 13.

PMID:
22327131
10.

Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Chen DF, Prasad VK, Broadwater G, Reinsmoen NL, DeOliveira A, Clark A, Sullivan KM, Chute JP, Horwitz ME, Gasparetto C, Long GD, Yang Y, Chao NJ, Rizzieri DA.

Bone Marrow Transplant. 2012 Jun;47(6):817-23. doi: 10.1038/bmt.2011.181. Epub 2011 Dec 5.

11.

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Horwitz ME, Chute JP, Gasparetto C, Long GD, McDonald C, Morris A, Rizzieri DA, Sullivan KM, Chao NJ.

Bone Marrow Transplant. 2012 Aug;47(8):1051-5. doi: 10.1038/bmt.2011.217. Epub 2011 Nov 14.

12.

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.

Kanda J, Horwitz ME, Long GD, Gasparetto C, Sullivan KM, Chute JP, Morris A, Hennig T, Li Z, Chao NJ, Rizzieri DA.

Bone Marrow Transplant. 2012 May;47(5):700-5. doi: 10.1038/bmt.2011.158. Epub 2011 Aug 1.

13.

Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.

Rizzieri DA, Crout C, Storms R, Golob J, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Lagoo AS, Morris A, Beaven A, Yang Y, Peterson B, Li Z, Chao NJ.

Cancer Invest. 2011 Jan;29(1):56-61. doi: 10.3109/07357907.2010.535055.

14.

Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Kanda J, Rizzieri DA, Gasparetto C, Long GD, Chute JP, Sullivan KM, Morris A, Smith CA, Hogge DE, Nitta J, Song K, Niedzwiecki D, Chao NJ, Horwitz ME.

Biol Blood Marrow Transplant. 2011 Jun;17(6):867-74. doi: 10.1016/j.bbmt.2010.09.009. Epub 2010 Sep 22.

15.

Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.

Crout CA, Koh LP, Gockerman JP, Moore JO, Decastro C, Long GD, Diehl L, Gasparetto C, Niedzwiecki D, Edwards J, Prosnitz L, Horwitz M, Chute J, Morris A, Davis P, Beaven A, Chao NJ, Ali-Osman F, Rizzieri DA.

Cancer Invest. 2010 Jul;28(6):654-60. doi: 10.3109/07357901003631015.

PMID:
20521909
16.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

17.

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.

Rizzieri DA, Dev P, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Chao NJ.

Bone Marrow Transplant. 2009 Feb;43(4):327-33. doi: 10.1038/bmt.2008.321. Epub 2008 Oct 13.

18.

Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection.

Byrne BJ, Horwitz M, Long GD, Gasparetto C, Sullivan KM, Chute J, Chao NJ, Rizzieri DA.

Bone Marrow Transplant. 2008 Jan;41(1):39-43. Epub 2007 Nov 5.

PMID:
17982503
19.

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Liu C, Marshall D, Vredenburgh JJ, Gockerman J, Decastro C, Moore J, Chao NJ.

J Clin Oncol. 2007 Feb 20;25(6):690-7. Epub 2007 Jan 16.

PMID:
17228020
20.

Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment.

Lagoo AS, Gong JZ, Stenzel TT, Goodman BK, Buckley PJ, Chao NJ, Gasparetto C, Long GD, Rizzieri DA.

Arch Pathol Lab Med. 2006 Oct;130(10):1479-88.

PMID:
17090189

Supplemental Content

Loading ...
Support Center